Page 42 - ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shore Fire Clients Perform, Present and Win at the 2021 Grammys

Shore Fire Clients Perform, Present and Win at the 2021 Grammys
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesDiane warrenLinda ronstadtMarvin gayeCarole kingJeffrey friedmanJacob collierRob epsteinJames taylorLos angelesTerri lyne carringtonSarah jaroszExchange commissionLos angeles convention centerDolphin entertainment inc

Intec Pharma and Decoy Biosystems Announce Merger Agreement

Intec Pharma and Decoy Biosystems Announce Merger Agreement USA - English Investigational New Drug Application Filing Expected in 2H 2021 News provided by Share this article Share this article JERUSALEM, March 15, 2021 /PRNewswire/ Intec Pharma Ltd. (NASDAQ: NTEC) ( Intec or the Company ) announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses. The combined company will advance its immunotherapy platform to battle a variety of tumor types and chronic viral infections. Decoy previously held a pre-IND meeting with the FDA, currently plans to file an IND in the second half of 2021 and to initiate a Phase I clinical trial in 2022 targeting solid tumors and lymphomas.

Israel generalSan diegoUnited statesWintec pharmaRoger pomerantzHar hotzvimMichaelj newmanJeffreya mecklerPrnewswire intec pharma ltdIntec pharma ltdCompany current report on formDecoy biosystems incCompany accordion pillDecoy biosystemsVice chairmanChief executive officer

ViewRay Announces Departure of Chief Operating Officer

ViewRay Announces Departure of Chief Operating Officer News provided by Share this article Share this article CLEVELAND, March 15, 2021 /PRNewswire/ ViewRay, Inc. (Nasdaq: VRAY) ( the Company ) today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021. Matin was named Chief Executive Officer designate of Cordis in its recently announced divestiture from Cardinal Health to private equity firm Hellman & Friedman. It has been a privilege to work alongside the ViewRay team, and I believe that MRIdian is unequivocally the future of radiation oncology, said Shahriar Matin, Chief Operating Officer. Departing ViewRay is difficult, but I am confident that the team we have built will execute on the opportunity to become standard of care.

Hellman friedmanShahriar matinScott drakeExchange commissionPrnewswire viewray incCardinal healthViewray incChief operating officerChief executive officerChief operatingChief executive officer scottGuided radiation therapyPrivate securities litigation reformLinac systemAnnual reportQuarterly reports

TopBuild Announces Closing of Senior Unsecured Notes Offering

TopBuild Announces Closing of Senior Unsecured Notes Offering March 15, 2021 08:15 ET | Source: TopBuild Corp. TopBuild Corp. DAYTONA BEACH, Fla., March 15, 2021 (GLOBE NEWSWIRE) TopBuild Corp. (NYSE:BLD), a leading purchaser, installer and distributor of insulation products to the U.S. construction industry, has closed its previously announced private offering of $400.0 million in aggregate principal amount of 3.625% senior notes due 2029. The Company has used the net proceeds from the offering, together with cash on hand, to redeem its existing $400 million 5.625% senior unsecured notes maturing in 2026 and to pay fees and expenses related to the offering. The notes have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements. This announcement does not constitute an

United statesDaytona beachTabitha zaneExchange commissionTopbuild corpService partnersBuild corpSecurities actPrivate securities litigation reformNyse bldஒன்றுபட்டது மாநிலங்களில்பகல்நேரம் கடற்கரைட்யாபித ஜேன்பரிமாற்றம் தரகுசேவை கூட்டாளர்கள்கட்ட கார்ப்

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45 5M Private Financing

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45 5M Private Financing
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United kingdomChristian angermayer presightPeter thielAnchiano adssSharon elkobiApeiron investment groupAnchiano therapeutics ltdAnchiano therapeutics ltd contactBusiness developmentChemomab ltdAnchiano therapeuticsAnchianoamerican depositary sharesChemomabincluding cormorant asset managementChristian angermayer presight capitalPrimary sclerosing cholangitisSystemic sclerosis